Levact (Bendamustine Hydrochloride)

Bendamustine hydrochloride acts by forming covalent bonds with DNA, creating cross‑links that block DNA replication and transcription. This interference triggers cell‑cycle arrest, particularly at the G2/M checkpoint, and activates apoptotic pathways in rapidly dividing malignant lymphocytes. Its dual alkylating and antimetabolite properties also impair DNA repair mechanisms, enhancing cytotoxicity against cancer cells.

The dosing regimen for Levact is individualized and determined by the prescribing oncologist. Dosage depends on factors such as the specific indication, patient body surface area, renal and hepatic function, and prior treatment history. Physicians calculate the appropriate amount and schedule, which is then administered intravenously under medical supervision.

Bendamustine hydrochloride is classified as contraindicated for use in pregnancy and lactation unless the potential therapeutic benefit justifies the risk. Animal studies have shown embryotoxic effects, and there is a lack of adequate human data. Women of childbearing potential should use effective contraception, and breastfeeding should be avoided during treatment.

To place an order, submit an enquiry on the Levact product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The team then confirms pricing, availability, shipping conditions—including any cold‑chain requirements—and assists with necessary import documentation.

Levact (bendamustine) is often compared with other alkylating agents such as cyclophosphamide or with newer targeted therapies like ibrutinib for CLL. Clinical studies have shown comparable response rates to some regimens, with a distinct toxicity profile that includes pronounced myelosuppression but lower rates of certain neuropathic side effects. Choice of therapy depends on disease characteristics, prior treatments, and patient tolerance.

Levact should be stored refrigerated at 2–8 °C (36–46 °F). The product must be kept in its original container, protected from light, and should not be frozen or shaken. Prior to administration, the solution is typically diluted with an appropriate IV fluid under aseptic conditions, and any unused portion should be discarded according to local regulations.

Levact is given as an intravenous infusion, usually over 30–60 minutes, depending on the prescribed dose and institutional protocol. The infusion is performed in a clinical setting where vital signs and infusion reactions can be monitored. Premedication with anti‑emetics or antihistamines may be used to reduce the risk of infusion‑related adverse events.

The most serious adverse events linked to Levact include severe myelosuppression leading to neutropenia, infections, and febrile neutropenia; secondary malignancies; and rare but potentially fatal hypersensitivity reactions. Patients should be closely monitored for signs of infection, bleeding, or allergic response, and dose adjustments or discontinuation may be required based on severity.

Levact is contraindicated in patients with known hypersensitivity to bendamustine or any of its excipients. It should also be avoided in individuals with uncontrolled active infections, severe hepatic impairment, or those who are pregnant or breastfeeding unless the benefit outweighs the risk. Caution is advised for patients with compromised bone‑marrow function, and treatment decisions should be individualized by the treating physician.